Healthy lifestyle and mortality in osteoarthritis

A prospective cohort study of the UK Biobank

2023-06-01

(Press-News.org) In this work, data from the UK Biobank were used to investigate the association of both individual and combined healthy lifestyle factors with the risk of all-cause and cause-specific mortality among 104,142 people with osteoarthritis.

The researchers gave each person a score for their lifestyle, based on their body mass index (BMI) and self-reported diet, sleep duration, physical activity, sedentary time, social connection, smoking, and alcohol drinking – all factors thought to be associated with health.

Overall, there were 9,915 deaths recorded after the first 2 years’ follow-up. Models showed a variety of associations between people’s lifestyle and mortality. Sleep duration had a U-shaped relationship, whilst moderate physical activity was L-shaped, and BMI and vigorous activity were J-shaped – a trend that starts with a sharp drop and is followed by a dramatic rise.

For sleep, the ideal seems to be 7 hours a night, whilst the turning point for moderate physical activity was 550 minutes per week, and 240 minutes per week for vigorous physical activity. The J-shaped turning point for BMI was 28 kg/m2.

In multivariable models, each lifestyle factor was significantly associated with all-cause mortality, as well as mortality associated with cancer, cardiovascular, digestive, and respiratory diseases.

This study could be important in helping to identify a healthy lifestyle pattern that could significantly reduce the risk of mortality in people with osteoarthritis. Indeed, EULAR has recently published recommendations on lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases, including osteoarthritis.1 The overarching principles define the importance of a healthy lifestyle, how lifestyle modifications should be implemented, and their role in relation to medical treatments.1 It seems now this could possibly benefit mortality as well as disease outcomes.

Source:

Fan T, et al. Association of Healthy Lifestyles with All-Cause and Cause-Specific Mortality Among Individuals with Osteoarthritis: A Prospective Cohort Study of the UK Biobank. Presented at EULAR 2023; Abstract OP0144.

References:

1. Gwinnutt JM, et al. 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. Ann Rheum Dis 2023;82:48–56

About EULAR

EULAR is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with rheumatic and musculoskeletal diseases (RMDs). EULAR aims to reduce the impact of RMDs on individuals and society, as well as improve RMD treatments, prevention, and rehabilitation. To this end, EULAR fosters excellence in rheumatology education and research, promotes the translation of research advances into daily care, and advocates for the recognition of the needs of those living with RMDs by EU institutions.

Contact
EULAR Communications, communications@eular.org

Notes to Editors
EULAR Recommendations
EULAR School of Rheumatology
EULAR Press Releases

END

ELSE PRESS RELEASES FROM THIS DATE:

The European Alliance of Associations For Rheumatology, EULAR, announces its strategy for 2024 – 2028

2023-06-01

Over the period 2018 – 2023, EULAR, the leading organisation in RMDs, has grown substantially and has been professionalised in every aspect. For example, EULAR has increased its impact on RMDs through the development of new services provided by the EULAR Research Centre (ERC). Despite the disruption of routine procedures brought about by the pandemic, EULAR overcame the substantial associated challenges, providing continued access to education and networking for the RMD community. “We have made tremendous progress by setting up two virtual congresses and one fully hybrid congress, and we have ...

EULAR launches ‘RheumaFacts’, a unique and Pan-European data repository of rheumatic and musculoskeletal disease indicators

2023-06-01

The European Alliance of Associations for Rheumatology (EULAR) is proud to announce the launch of RheumaFacts, an innovative and unique resource of facts and figures related to rheumatic and musculoskeletal diseases (RMDs) across Europe. Strategically developed to support EULAR’s mission of reducing the impact of RMDs on individuals and society, RheumaFacts will serve as a powerful tool to provide healthcare professionals, researchers, policymakers, and patients with data-driven insights on the status of rheumatologic care across EULAR’s ...

EULAR launches first European patient-filled survey about the impact of rheumatic and musculoskeletal diseases on individual’s lives

2023-06-01

The European Alliance of Associations for Rheumatology (EULAR) has announced the launch of the EULAR Impact of RMDs Survey, an online questionnaire targeted directly at RMD patients. The data collected through this survey will be an important resource for researchers, healthcare professionals, and patients alike, providing a comprehensive database of patient-reported outcomes on their healthcare situation, and how the illness affects their social and occupational lives. By collecting and analysing data from a large number of patients with RMDs on a recurring basis, the survey will provide valuable insights into the burden of disease and help improve the overall care for people living with ...

Rheumatic and musculoskeletal diseases (RMDs) often accelerate lethal comorbidities

2023-06-01

Rheumatic and musculoskeletal diseases (RMDs) include over 200 diseases that affect over 120 million Europeans of all ages. Aside from the significant direct impact RMDs have on patients, many of them also pose a further significant risk to the population by virtue of accelerating many comorbidities if the RMD is not treated appropriately. The most significant comorbidities of inflammatory RMDs include cardiovascular disease, lung disease, cancers, gastrointestinal disease, and mental health disorders.[1] Many of these comorbidities are prioritised by the EU as key non-communicable ...

Stand Up to Cancer announces $1.5 million commitment from Pancreatic Cancer North America to fund pancreatic cancer vaccine research

2023-06-01

LOS ANGELES – June 1, 2023 – Stand Up To Cancer® (SU2C) and Pancreatic Cancer North America (PCNA) today announced that PCNA will contribute $1.5 million to SU2C in support of critically needed research focused on pancreatic cancer, which has the highest mortality rate of all major cancers. One of the projects supported by PCNA will include a correlative study that analyzes data from a previous Phase 1 clinical trial conducted by a Research Team funded through the SU2C Convergence program and led by researchers at Memorial ...

Rethink, rewrite, redefine—how biodegradable plastics are reshaping sustainability

2023-06-01

The University of California San Diego’s vision is to be a student-centered, research-focused, service-oriented public university. There are countless examples across campus of the ways these three pillars are upheld, but it is unique to find all three incorporated at once. Now a new book on algae-based biodegradable plastics showcases student research and the monumental potential it has to change consumerism on a global scale. Statistics on the environmental damage of plastics are stark: in 2018, U.S. landfills received 27 million tons of plastic (U.S. Environmental Protection Agency); ...

ComboMATCH investigators are translating robust pre-clinical evidence for new anti-cancer drug combinations into a series of early-phase clinical trials

2023-06-01

Five leading cancer research organizations in the United States are jointly announcing the start of patient enrollment in Molecular Analysis for Combination Therapy Choice (ComboMATCH), a unique, precision medicine initiative to test new combinations of cancer drugs guided by tumor biology. The Alliance for Clinical Trials in Oncology, Children's Oncology Group, ECOG-ACRIN Cancer Research Group, NRG Oncology, and SWOG Cancer Research Network plan to conduct many early-phase treatment trials through this platform in collaboration with the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). NCI is part of ...

Parkinson’s disease drug ropinirole safely slowed the progression of ALS for over 6 months in a clinical trial

2023-06-01

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a fatal motor neuron disease that causes people to gradually lose control of their muscles. There is no cure, and current treatments focus on reducing symptoms and providing supportive care. Reporting June 1 in the journal Cell Stem Cell, researchers from Japan show in an early clinical trial that the Parkinson’s disease drug ropinirole is safe to use in ALS patients and delayed disease progression by 27.9 weeks on average. Some patients were more responsive to ropinirole treatment than others, and the researchers ...

The 'breath' between atoms — a new building block for quantum technology

2023-06-01

University of Washington researchers have discovered they can detect atomic "breathing," or the mechanical vibration between two layers of atoms, by observing the type of light those atoms emitted when stimulated by a laser. The sound of this atomic "breath" could help researchers encode and transmit quantum information. The researchers also developed a device that could serve as a new type of building block for quantum technologies, which are widely anticipated to have many future applications in fields such as computing, ...

CHOP researchers use “deep sequencing” to identify several previously undescribed genetic variants in vascular anomalies

2023-06-01

Philadelphia, June 1, 2023 – Researchers from Children’s Hospital of Philadelphia (CHOP) recently discovered that extremely thorough “deep sequencing” of the genome in tissue samples and cell-free DNA of patients with potentially life-threatening vascular anomalies captured several genetic variants related to disease that were not captured with conventional genetic sequencing methods. More than 60% of patients saw an improvement in their condition after being placed on targeted therapies related to these newly found genetic variants. The findings were published today in the journal Nature Medicine. Vascular ...

Healthy lifestyle and mortality in osteoarthritis

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: